Cadila Healthcare has acquired Melgain lotion used for treatment of skin depigmentation from Issar Pharma to strengthen its dermatological portfolio. Melgain will be marketed in India by Liva Healthcare, a specialty division of the group catering to the dermatological segment. Melgain is used for the treatment of Vitiligo, a chronic skin condition characterized by portions of the skin losing their pigment.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
